Roundtable discussion—Multiple Myeloma Hub Satellite Symposium: Should 'cure' be the goal for MM?

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma?

This video captures the roundtable discussion with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University (Paris, FR), María-Victoria Mateos, University Hospital of Salamanca (Salamanca, ES), and Sagar Lonial, Winship Cancer Institute of Emory University (Atlanta, US), and includes the concluding remarks of the Satellite Symposium as a whole.

Questions that were answered include:

Do we think that the cure vs chronic disease model may be differentially applicable based on genetics? (00:16)

What do you define as acceptable safety profiles for smoldering multiple myeloma (SMM), and where do you set the bar? (04:42)

Does it make a difference to treat SMM patients earlier rather than wait for them to develop IMWG-defined progression? (09:48)

Does immune status/immune function impact the ability to ultimately cure subsets of patients? (13:44)

What do you think of Sagar Lonial's 'siren song' of MRD response? (17:55)

Comment on the curative potential of allogeneic transplant (21:07)

Can you wake the immune senescence with interferon? (22:50)

Final remarks by Sagar Lonial (24:30)

Find below links to the talks from the symposium:

'Does 'cure' have a different meaning in MM?' presented by Mohamad Mohty.  

'Is the treatment of high-risk smoldering multiple myeloma (SMM) the way for achieving the cure?' presented by María-Victoria Mateos. 

'Is transplantation still relevant? If yes, in which context?' presented by Sagar Lonial.

'Treating elderly and frail patients with MM: Cure versus disease control' presented by Vincent Rajkumar.